SORRENTO THERAPEUTICS, INC. Form 8-K (April 4, 2022)

Summary

Current report on Form 8-K for an event dated April 4, 2022, filed by Sorrento Therapeutics, Inc. Under Item 2.02, the report states that on April 4, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento, issued a press release announcing preliminary gross sales of ZTlido (lidocaine topical system) 1.8% of approximately $8.1 million during the month of March 2022, a 53% year-over-year increase, and approximately $18.4 million for the first quarter of 2022, a 26% year-over-year increase. The press release is furnished as Exhibit 99.1. Henry Ji signed on April 4, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): April 4, 2022

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified
in its Charter)

Delaware | 001-36150 | 33-0344842
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

4955 Directors Place

San Diego , CA 92121

(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number,
including area code: ( 858 ) 203-4100

N/A

(Former Name, or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.0001 par value | SRNE | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial
Conditions.

On April 4, 2022, Scilex Holding Company (“Scilex”),
a majority-owned subsidiary of Sorrento Therapeutics, Inc., issued a press release announcing preliminary gross sales of Scilex’s
ZTlido® (lidocaine topical system) 1.8%, of approximately (i) $8.1 million during the month of March 2022, a 53% year-over-year increase,
and (ii) $18.4 million for the first quarter of 2022, a 26% year-over-year increase. A copy of the press release is furnished as Exhibit
99.1 to this Current Report on Form 8-K.

In accordance with General Instructions B.2 of
Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that
section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of
1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference
in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibit.

99.1 | Press Release of Scilex Holding Company, dated April 4, 2022.
104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.
Date: April 4, 2022 | By: | /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman of the Board, President and Chief Executive Officer

File and source

File

SEC_SRNE_8-K_filed2022-04-04_0001104659-22-041997.htm

Size

25,356 bytes

SHA-256

010205894c1ec0dd7d5c2de4e07dc4bcb9ff7ce9393365a4b46d982a90c1745d

Our copy

SEC_SRNE_8-K_filed2022-04-04_0001104659-22-041997.htm

Original

www.sec.gov